Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Jarvenpaa

20 clinical trials in Jarvenpaa, Finland. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Jarvenpaa at a glance
20
clinical trials
  • Recruiting now0
  • Research sites0
Type of trial
Recruitment status
Quick filters

20 trials in Jarvenpaa

Open in trial search

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Not yet recruiting
Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Sanofi Pasteur Inc.

Metapneumovirus infection

Not yet recruiting
Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:HUMAN METAPNEUMOVIRUS, VIRUS-LIKE PROTEIN
  • Sponsor:AstraZeneca AB

Pneumococcal immunisation

Not yet recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
  • Sponsor:Pfizer Inc.

Influenza+1

Not yet recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:GlaxoSmithKline Biologicals

Pneumococcal immunisation

Not yet recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
  • Sponsor:Pfizer Inc.

Respiratory syncytial virus infection+3

Not recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Cytomegalovirus immunisation

Not recruiting
Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Inc.

Meningococcal infection

Not recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:GlaxoSmithKline Biologicals

Influenza immunisation

Not recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Respiratory syncytial virus infection

Not recruiting
Investigational
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:534
  • Sponsor:Sanofi Pasteur Inc.

Meningococcal immunisation

Not recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:TETANUS TOXOID
  • Sponsor:Sanofi Winthrop Industrie

Meningococcal immunisation

Not recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:RNMB1
  • Sponsor:Sanofi Pasteur Inc.

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Jarvenpaa

What the registry says about research in the country

01 Respiratory Virus Prevention

Innovative research focusing on respiratory syncytial virus (RSV) and influenza vaccines, evaluating new preventive approaches for both young and elderly populations.

  • RSV vaccine development for seniors
  • Influenza vaccine efficacy studies
  • Combined viral protection research

Multiple clinical trials are exploring breakthrough vaccine technologies, including mRNA platforms.

02 Meningococcal Disease Research

Comprehensive studies on meningococcal vaccines targeting multiple disease strains, with particular focus on protecting infants and young children.

  • Pentavalent vaccine development
  • Long-term immunity studies
  • Pediatric vaccination protocols

Research aims to enhance protection against various meningococcal serogroups through innovative conjugate vaccines.

03 Viral Disease Prevention

Advanced research into preventing cytomegalovirus and herpes zoster infections, utilizing cutting-edge vaccine technologies.

  • CMV prevention strategies
  • Herpes zoster vaccine efficacy
  • Pneumococcal protection studies

These trials focus on developing robust immune responses in specific target populations.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.